Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
Sermorelin reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
Sermorelin is a synthetic peptide corresponding to the first 29 residues of endogenous ghrh of 29 amino acids. The first 29 residues of endogenous growth hormone-releasing hormone, GHRH(1-44).
Reported to bind GHRH receptors on anterior pituitary somatotroph cells, stimulating synthesis and pulsatile secretion of endogenous growth hormone. Vectra makes no claim as to mechanism or effect.
Sermorelin HAS held FDA approval, both as a therapeutic and as a diagnostic agent. It was withdrawn in 2008 for commercial reasons, not for safety. A withdrawn approval is not the same as a rejected one, and neither makes this material an approved product.
Identified in the early 1980s. More than twenty human clinical trials are on record across paediatric and adult populations, including Khorram et al. (1997), Vitiello et al. (2006), and work by Corpas and colleagues.
Studied as a growth hormone diagnostic agent and in paediatric growth hormone deficiency. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
Strongly indication-specific: 5 of 5 as a growth hormone diagnostic test, 4 of 5 in paediatric growth hormone deficiency, and 2–3 of 5 for most other indications. This is the best-evidenced compound in the catalog, and the rating is still indication-bound. A 5-of-5 diagnostic rating says nothing about any other use.
Injection-site reactions are very common, above 10%. Facial flushing, headache, nausea and dizziness are common, at 1–10%. Contraindicated in active malignancy.
Our sources carry no CAS number, formula, molecular weight, sequence, or storage data for Sermorelin.
Previously FDA-approved; withdrawn 2008 for commercial reasons. Notably, sermorelin survived the FDA's September 2024 peptide compounding restrictions and remains available through US compounding pharmacies. No therapeutic, preventive, or diagnostic claims are made or implied.
Yes — in more than one way:
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
Compatibility does not assert current availability. No preparation, ratio, or protocol guidance renders here.